cardiovascular disease
Conditions
Interventions
Group 1:JIENING aspirin 50mg/d
Group 2:JIENING aspirin 100mg/d
Group 3:Bay-aspirin 100mg/d
Sponsors
Peking University First Hospital
Eligibility
Sex/Gender
All
Age
60 Years to No maximum
Inclusion criteria
Inclusion criteria: For primary prevention: enroll high risk CVD populations who need aspirin treatment, and meet the following criteria: 1. aged at least 60 years, and able to take care of themselves; 2. at least one of the following combined diseases: Hypertension, Diabetes, hyperlipidemia; 3. at least two of the following circumstances: smoking history, obesity(BMI index=28 kg/m2), Family history of early onset cardiovascular disease; 4. on or not on aspirin treatment for the primary prevention of CVD; 5. volunteer for this study with informed consents. For secondary prevention: enroll stable coronary artery disease patients on long-term aspirin treatment, and meet the following criteria: 1. aged at least 60 years, and able to take care of themselves; 2. diagnosed as coronary artery disease, on or not on aspirin treatment for the secondary prevention of CVD; 3. stable patients with previous history of PCI for more than 1 year, on aspirin treatment; 4. volunteer for this study with informed consents.
Exclusion criteria
Exclusion criteria: Exclusion criteria: (1) contra-indictions or allergy to aspirin, high bleeding risk patients, such as those with history of erosive gastritis, peptic ulcer or hemorrhage, intracranial hemorrhage; (2) platelet count less than <80×10^9/L; (3) combined with other NSAIDs or hormones; (4)not suitable for enrollment after clinical evaluation, such as uncontrolled hypertension, malignant tumor or severe renal/liver dysfunction; (5) combined with other antiplatelet drugs, including clopidogrel, cilostazol and ticargrelor, or anticoagulants such as warfarin, dabigatran and rivaroxaban; (6) stenosis in left main coronary artery or severe triple vessel disease; (7) patients with poor compliance; (8) those who drop out during the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Arachidonic Acids-induced platelet aggregation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Fecal occult blood test; | — |
Countries
China
Contacts
Public ContactLiu Meilin
Department of Geriatric, Peking University First Hospital
Outcome results
None listed